Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06408727
Status:
AVAILABLE
Last Update Posted:
2024-05-22
First Post:
2024-04-24
Brief Title:
Intermediate Expanded Access Protocol CNMAu8EAP04
Sponsor:
Clene Nanomedicine
Organization:
Clene Nanomedicine
Study Overview
Official Title:
An Intermediate Expanded Access Protocol With CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012
Status:
AVAILABLE
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An Intermediate Expanded Access Protocol EAP with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012
Detailed Description:
An Intermediate Expanded Access Protocol EAP with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012 The primary objective of this intermediate EAP is to provide access to the investigational product CNM-Au8 30mg for up to 180 people living with ALS
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1U01NS136023-01 | NIH | None | httpsreporternihgovquickSearch1U01NS136023-01 |